Cocrystalline forms of a bruton's tyrosine kinase inhibitor
AssigneeLoxo Oncology, Inc.
InventorsDavid Andrew COATES, Lori Raquel HILDEN
Life of this patent
Estimating the term…
Abstract
Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of making these cocrystalline forms.
Claims46
1-34. (canceled)
A crystalline form of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide comprising the following formula:
A crystalline form of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide comprising the following formula:
Dependencies are inferred from the claim text.